Satellos Bioscience (TSE:MSCL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Satellos Bioscience, a biotech firm focusing on muscle disease treatments, announced CEO Frank Gleeson will join a panel at the PPMD Annual Conference to discuss their progress, particularly their investment-backed oral drug candidate aimed at treating Duchenne muscular dystrophy. The company is preparing to submit a regulatory package for a Phase 1 clinical trial of SAT-3247, a novel drug designed to restore muscle regeneration. SAT-3247, which targets the underlying cause of muscle loss in degenerative diseases, is anticipated to enter human trials in the third quarter of 2024.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
